LumiThera receives $500,000 grant to help bring photobiomodulation device to market

May 28, 2015

A grant worth $500,000 could help bring a treatment for dry age-related macular degeneration (AMD) to market.

Low-level laser therapy (LLLT) system maker LumiThera (Poulsbo, WA) has been awarded a Washington State Life Sciences Discovery Fund (LSDF) commercialization grant worth $500,000 to help bring a treatment for subjects with dry age-related macular degeneration (AMD) to market.

Related: Low-level laser therapy: Treatment through precise application of light

Clark Tedford, Ph.D., LumiThera's president and CEO, explains that a seed grant allowed the company to build a noninvasive photobiomodulation prototype instrument and that the matching investor commercialization grant will allow them to complete the commercial product development. The grant with investor matching funds will further support initiation of a pivotal clinical trial in late 2015 in subjects that have dry AMD, he adds.

The grant also provides for collaboration between LumiThera and Product Creation Studio (PCS; Seattle, WA), a design house that has been working with the company to create the instrument.

For more information, please visit www.lumithera.com.

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)